Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Generate Biomedicines, Inc.NASDAQ: GENB

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit of $3.95M in Q1 FY2026

Q1 FY2026 gross profit was $3.95M.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.95M— QoQ
Last fiscal yearDec 2025
$31.89M+55.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+55.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
31.89M USD
Year-over-year change
+55.9%
1-year CAGR
+55.9%

Gross Profit vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 gross profit of $31.89M is the 2nd highest of the 5 companies compared; the peer median is -$6.86M.
  • Its year-over-year change of +55.9% is the highest of 5, against a peer median of +47.2%.
  • Gross profit amounts to 100.0% of revenue for GENB, versus a peer median of 89.6%.
GENB Competitors Peer median
Gross Profit for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M +52.1%+17.0%98.7%
GENBGenerate Biomedicines, Inc.FY2025$31.89M +55.9%—100.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026-$1.05M +45.7%—80.4%
ABCLAbCellera Biologics Inc.LTM Sep 2026-$12.67M -135.9%-52.0%18.7%
ABSIAbsci CorporationLTM Mar 2026-$24.18M +48.7%—1316.9%
Peer median (excluding GENB) -$6.86M+47.2%-17.5%89.6%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.46M31.89M
Cost of Revenue00
Gross Profit20.46M31.89M
Gross Margin100.0%100.0%
Research & Development175.31M224.7M
Selling, General & Admin42.09M42.26M
Operating Expenses217.4M266.96M
Depreciation & Amortization15.35M13.18M
EBITDA(163.71M)(208.49M)
EBITDA Margin-800.2%-653.7%
Operating Income(196.94M)(235.07M)
Operating Margin-962.6%-737.0%
Interest Income18.12M13.66M
Interest Expense2.12M1.14M
Other Income / Expenses15.77M12.26M
Income Before Tax(181.17M)(222.8M)
Pre-Tax Margin-885.5%-698.6%
Income Tax Expense212K163K
Net Income(173.77M)(203.15M)
Net Margin-849.4%-637.0%
EPS (Basic)(1.68)(4.98)
EPS (Diluted)(1.68)(4.98)
Weighted Avg Shares127.45M50.09M
Weighted Avg Shares (Diluted)127.45M50.09M

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.